TY - JOUR
T1 - Effects of oral administration of a stimulator for nerve growth factor synthesis in basal forebrain-lesioned rats
AU - Nitta, Atsumi
AU - Murase, Katsuhito
AU - Furukawa, Yoshiko
AU - Hayashi, Kyozo
AU - Hasegawa, Takaaki
AU - Nabeshima, Toshitaka
N1 - Funding Information:
We are grateful to Takeda Chemical Industries, Ltd. (Osaka, Japan) for supplying TMQ. This study was supported in part by a SRF grant for Biomedical Research and grants from the Sandoz Foundation for Gerontological Research, the Ministry of Education, Science and Culture, Japan (No. 05454148) and the Ministry of Health and Welfare Foundation for Gerontological Science Research (91A-2406).
PY - 1993/11/30
Y1 - 1993/11/30
N2 - Nerve growth factor plays an important role in the survival and maintenance of cholinergic neurons in the central neuronal system. In senile dementia of the Alzheimer type, learning and memory are impaired by the loss of neurons in the magnocellular cholinergic neuronal system. It is, therefore, of interest to investigate the role of nerve growth factor in senile dementia of the Alzheimer type. We now found that 6-(4-hydroxybutyl)-2,3,5-trimethyl-1,4-benzoquinone (TMQ) stimulates nerve growth factor synthesis in mouse astroglial cells and that the compound has improving effects on memory and choline acetyltransferase activity in basal forebrain-lesioned rats, an amnesia animal model. TMQ ameliorated amnesia in the water maze and passive avoidance tasks. The compound not only restored the reduced choline acetyltransferase activity in the parietal cerebral cortex, but also increased nerve growth factor content and choline acetyltransferase activity in the hippocampus, although it did not change either of these parameters in any brain region in intact rats. These results suggest that the compound activates cholinergic neurons only in the damaged brain and, further, indicate that nerve growth factor stimulators could be used in clinical trials for the treatment of senile dementia of the Alzheimer type.
AB - Nerve growth factor plays an important role in the survival and maintenance of cholinergic neurons in the central neuronal system. In senile dementia of the Alzheimer type, learning and memory are impaired by the loss of neurons in the magnocellular cholinergic neuronal system. It is, therefore, of interest to investigate the role of nerve growth factor in senile dementia of the Alzheimer type. We now found that 6-(4-hydroxybutyl)-2,3,5-trimethyl-1,4-benzoquinone (TMQ) stimulates nerve growth factor synthesis in mouse astroglial cells and that the compound has improving effects on memory and choline acetyltransferase activity in basal forebrain-lesioned rats, an amnesia animal model. TMQ ameliorated amnesia in the water maze and passive avoidance tasks. The compound not only restored the reduced choline acetyltransferase activity in the parietal cerebral cortex, but also increased nerve growth factor content and choline acetyltransferase activity in the hippocampus, although it did not change either of these parameters in any brain region in intact rats. These results suggest that the compound activates cholinergic neurons only in the damaged brain and, further, indicate that nerve growth factor stimulators could be used in clinical trials for the treatment of senile dementia of the Alzheimer type.
UR - http://www.scopus.com/inward/record.url?scp=0027332575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027332575&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(93)90616-P
DO - 10.1016/0014-2999(93)90616-P
M3 - Article
C2 - 8119322
AN - SCOPUS:0027332575
SN - 0014-2999
VL - 250
SP - 23
EP - 30
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -